NO324844B1 - Farmasoytisk preparat omfattende CPT-11 og combretastatin og anvendelse for behandling av cancer. - Google Patents
Farmasoytisk preparat omfattende CPT-11 og combretastatin og anvendelse for behandling av cancer. Download PDFInfo
- Publication number
- NO324844B1 NO324844B1 NO20031656A NO20031656A NO324844B1 NO 324844 B1 NO324844 B1 NO 324844B1 NO 20031656 A NO20031656 A NO 20031656A NO 20031656 A NO20031656 A NO 20031656A NO 324844 B1 NO324844 B1 NO 324844B1
- Authority
- NO
- Norway
- Prior art keywords
- combretastatin
- cpt
- combination
- treatment
- pharmaceutical preparation
- Prior art date
Links
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 title claims description 53
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 title claims description 53
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title claims description 45
- 206010028980 Neoplasm Diseases 0.000 title claims description 25
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 17
- 238000011282 treatment Methods 0.000 title claims description 13
- 201000011510 cancer Diseases 0.000 title description 5
- 238000002360 preparation method Methods 0.000 claims description 10
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000010897 colon adenocarcinoma Diseases 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 description 11
- 230000003000 nontoxic effect Effects 0.000 description 11
- 239000002246 antineoplastic agent Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 206010009944 Colon cancer Diseases 0.000 description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
- 101150073133 Cpt1a gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000003327 cancerostatic effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229960005537 combretastatin A-4 Drugs 0.000 description 1
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24343100P | 2000-10-27 | 2000-10-27 | |
| US24558200P | 2000-11-06 | 2000-11-06 | |
| US25013800P | 2000-12-01 | 2000-12-01 | |
| PCT/EP2001/012985 WO2002034244A2 (en) | 2000-10-27 | 2001-10-25 | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20031656L NO20031656L (no) | 2003-04-10 |
| NO20031656D0 NO20031656D0 (no) | 2003-04-10 |
| NO324844B1 true NO324844B1 (no) | 2007-12-17 |
Family
ID=27399663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20031656A NO324844B1 (no) | 2000-10-27 | 2003-04-10 | Farmasoytisk preparat omfattende CPT-11 og combretastatin og anvendelse for behandling av cancer. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6562834B2 (bg) |
| EP (1) | EP1333820A2 (bg) |
| JP (1) | JP2004517821A (bg) |
| KR (1) | KR100742524B1 (bg) |
| CN (1) | CN1200712C (bg) |
| AU (2) | AU1602902A (bg) |
| BG (1) | BG107806A (bg) |
| BR (1) | BR0114856A (bg) |
| CA (1) | CA2426898A1 (bg) |
| EA (1) | EA005400B1 (bg) |
| EE (1) | EE200300184A (bg) |
| HK (1) | HK1058623A1 (bg) |
| HR (1) | HRP20030382A2 (bg) |
| HU (1) | HUP0302629A3 (bg) |
| IL (1) | IL155509A0 (bg) |
| MX (1) | MXPA03002882A (bg) |
| NO (1) | NO324844B1 (bg) |
| NZ (1) | NZ524855A (bg) |
| PL (1) | PL365685A1 (bg) |
| SK (1) | SK5122003A3 (bg) |
| WO (1) | WO2002034244A2 (bg) |
| YU (1) | YU29803A (bg) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020183266A1 (en) * | 2001-03-15 | 2002-12-05 | Aventis Pharma, S.A. | Combination comprising combretastatin and anticancer agents |
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| CA2383259A1 (en) * | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| US20080075762A1 (en) * | 2001-10-03 | 2008-03-27 | Paul Tardi | Compositions for delivery of drug combinations |
| TW200819409A (en) | 2006-10-19 | 2008-05-01 | Univ Taipei Medical | Z-stilbenes derivatives and the pharmaceutical composition thereof |
| CA2826034A1 (en) | 2011-01-28 | 2012-08-02 | University Of Kentucky Research Foundation | Stilbene analogs and methods of treating cancer |
| AU2012275841A1 (en) | 2011-06-27 | 2014-01-16 | The Jackson Laboratory | Methods and compositions for treatment of cancer and autoimmune disease |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399276A (en) | 1981-01-09 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | 7-Substituted camptothecin derivatives |
| JPS57116015A (en) | 1981-01-09 | 1982-07-19 | Yakult Honsha Co Ltd | Antitumor agent |
| JPS57116074A (en) | 1981-01-09 | 1982-07-19 | Yakult Honsha Co Ltd | Novel camptothecin derivative and its preparation |
| US4473692A (en) | 1981-09-04 | 1984-09-25 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
| JPS58154582A (ja) | 1982-03-10 | 1983-09-14 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体およびその製造法 |
| JPS595188A (ja) | 1982-06-30 | 1984-01-12 | Yakult Honsha Co Ltd | １０−ヒドロキシカンプトテシンの製造法 |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| US4981968A (en) | 1987-03-31 | 1991-01-01 | Research Triangle Institute | Synthesis of camptothecin and analogs thereof |
| CA1332413C (en) | 1987-06-25 | 1994-10-11 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
| US5004758A (en) | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
| JPH0615547B2 (ja) | 1988-01-20 | 1994-03-02 | 株式会社ヤクルト本社 | 新規なカンプトテシン誘導体 |
| JP2524804B2 (ja) | 1988-03-29 | 1996-08-14 | 株式会社ヤクルト本社 | 新規なカンプトテシン誘導体及びその製造法 |
| JP2524803B2 (ja) | 1988-03-29 | 1996-08-14 | 株式会社ヤクルト本社 | 新規なカンプトテシン誘導体およびその製造法 |
| EP0540099B1 (en) | 1991-10-29 | 1996-04-17 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
| TW325458B (en) * | 1993-09-08 | 1998-01-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer |
| TW334418B (en) | 1995-03-07 | 1998-06-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions |
| US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
| GB9510716D0 (en) | 1995-05-26 | 1995-07-19 | Pharmacia Spa | Substituted camptothecin derivatives and process for their preparation |
| US5663177A (en) | 1995-05-31 | 1997-09-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs |
| US5670500A (en) | 1995-05-31 | 1997-09-23 | Smithkline Beecham Corporation | Water soluble camptothecin analogs |
| PT835258E (pt) | 1995-06-21 | 2003-02-28 | Sod Conseils Rech Applic | Novos analogos de camptotecina, processos para a sua preparacao, sua utilizacao como farmacos e composicoes farmaceuticas que os contem |
| JP3054669B2 (ja) | 1995-10-16 | 2000-06-19 | 余川商事株式会社 | 積雪落下防止装置 |
| JPH11296051A (ja) | 1998-04-08 | 1999-10-29 | Canon Inc | プロセスカートリッジ |
| DE69942128D1 (de) * | 1998-12-11 | 2010-04-22 | Coulter Pharm Inc | Prodrugs und verfahren zu deren herstellung |
| GB9903404D0 (en) * | 1999-02-16 | 1999-04-07 | Angiogene Pharm Ltd | Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis |
| CA2432792C (en) | 2000-12-22 | 2012-04-03 | Bristol-Myers Squibb Company | Methods for modulating tumor growth and metastasis |
-
2001
- 2001-10-25 EP EP01988584A patent/EP1333820A2/en not_active Withdrawn
- 2001-10-25 CA CA002426898A patent/CA2426898A1/en not_active Abandoned
- 2001-10-25 EE EEP200300184A patent/EE200300184A/xx unknown
- 2001-10-25 JP JP2002537298A patent/JP2004517821A/ja active Pending
- 2001-10-25 KR KR1020037005754A patent/KR100742524B1/ko not_active IP Right Cessation
- 2001-10-25 AU AU1602902A patent/AU1602902A/xx active Pending
- 2001-10-25 WO PCT/EP2001/012985 patent/WO2002034244A2/en active IP Right Grant
- 2001-10-25 SK SK512-2003A patent/SK5122003A3/sk not_active Application Discontinuation
- 2001-10-25 MX MXPA03002882A patent/MXPA03002882A/es not_active Application Discontinuation
- 2001-10-25 YU YU29803A patent/YU29803A/sh unknown
- 2001-10-25 NZ NZ524855A patent/NZ524855A/en unknown
- 2001-10-25 PL PL01365685A patent/PL365685A1/xx not_active Application Discontinuation
- 2001-10-25 BR BR0114856-7A patent/BR0114856A/pt not_active IP Right Cessation
- 2001-10-25 AU AU2002216029A patent/AU2002216029B2/en not_active Ceased
- 2001-10-25 EA EA200300516A patent/EA005400B1/ru not_active IP Right Cessation
- 2001-10-25 CN CNB018179800A patent/CN1200712C/zh not_active Expired - Fee Related
- 2001-10-25 HU HU0302629A patent/HUP0302629A3/hu unknown
- 2001-10-25 IL IL15550901A patent/IL155509A0/xx unknown
- 2001-10-26 US US09/984,043 patent/US6562834B2/en not_active Expired - Fee Related
-
2003
- 2003-04-10 NO NO20031656A patent/NO324844B1/no unknown
- 2003-05-12 BG BG107806A patent/BG107806A/bg unknown
- 2003-05-14 HR HR20030382A patent/HRP20030382A2/hr not_active Application Discontinuation
-
2004
- 2004-02-26 HK HK04101397A patent/HK1058623A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004517821A (ja) | 2004-06-17 |
| KR20030082544A (ko) | 2003-10-22 |
| NO20031656L (no) | 2003-04-10 |
| BG107806A (bg) | 2004-06-30 |
| IL155509A0 (en) | 2003-11-23 |
| HUP0302629A2 (hu) | 2003-11-28 |
| AU2002216029B2 (en) | 2006-01-05 |
| US20020115677A1 (en) | 2002-08-22 |
| HK1058623A1 (en) | 2004-05-28 |
| US6562834B2 (en) | 2003-05-13 |
| HUP0302629A3 (en) | 2005-05-30 |
| PL365685A1 (en) | 2005-01-10 |
| CN1471396A (zh) | 2004-01-28 |
| NO20031656D0 (no) | 2003-04-10 |
| EA200300516A1 (ru) | 2003-08-28 |
| HRP20030382A2 (en) | 2005-04-30 |
| WO2002034244A2 (en) | 2002-05-02 |
| MXPA03002882A (es) | 2004-12-03 |
| SK5122003A3 (en) | 2003-12-02 |
| BR0114856A (pt) | 2004-06-15 |
| KR100742524B1 (ko) | 2007-08-02 |
| EE200300184A (et) | 2003-08-15 |
| NZ524855A (en) | 2004-10-29 |
| AU1602902A (en) | 2002-05-06 |
| EA005400B1 (ru) | 2005-02-24 |
| WO2002034244A3 (en) | 2003-05-30 |
| CA2426898A1 (en) | 2002-05-02 |
| CN1200712C (zh) | 2005-05-11 |
| YU29803A (sh) | 2006-05-25 |
| EP1333820A2 (en) | 2003-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI386203B (zh) | 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用 | |
| WO2010012777A1 (en) | THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT | |
| EP2952184B1 (en) | Pharmaceutical formulation for treating pancreatic cancer | |
| EP1278518B1 (en) | Synergistic combination for the treatment of colorectal cancer | |
| NO332079B1 (no) | Anvendelse av picoplatina, docetaxel, paclitaxel og et ikke-platina ikke-taxan anti-cancermiddel for fremstilling av et medikament. | |
| JP2018517759A (ja) | カルボプラチンを含む組成物及び用途 | |
| NO324844B1 (no) | Farmasoytisk preparat omfattende CPT-11 og combretastatin og anvendelse for behandling av cancer. | |
| AU2002216029A1 (en) | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer | |
| EP3565547B1 (en) | Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof | |
| CN110496129A (zh) | 利拉利汀的抗肿瘤活性及其新用途 | |
| KR102176602B1 (ko) | 칼슘 신호를 경유하는 엑소좀 분비 조절 기술을 이용한 항암제 병용투여용 약학적 조성물 | |
| CN109789136B (zh) | 用于预防或治疗结肠直肠癌的药物联合组合物 | |
| JPH06505487A (ja) | 食道癌の治療用医薬組成物 | |
| CN111773388A (zh) | A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用 | |
| CA2465807A1 (en) | Use of bisindolmaleimide and gemcitabine for the treatment of cancer | |
| JP2007523187A (ja) | 癌を処置または予防するためのβ−ラパコンの使用 | |
| JPH06505741A (ja) | 非小細胞肺癌の治療 | |
| JP2003526659A (ja) | 癌の治療のためのカンプトテシンもしくはカンプトテシン誘導体およびアルキル化剤を含んで成る組成物 | |
| US20030195161A1 (en) | Composition comprising camptothecin or a camptothecin derivative and a topoisomerase II inhibitor for the treatment of cancer | |
| Perez et al. | Phase II study of amonafide in advanced and recurrent sarcoma patients | |
| ZA200302552B (en) | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer. | |
| Mélcon et al. | Phase 1/2 study of the selective TRK inhibitor larotrectinib, in pediatric patients with cancer | |
| CN110876803A (zh) | 一种包含乳蛋白和油酸的药物组合物 | |
| EP1599210A1 (en) | A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent | |
| WO2003059355A1 (en) | Quinazolinone compounds in combined modalities for improved cancer treatment |